secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001411690-24-000046
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano Q2 revenue $7.8M (-10% YoY); FY2024 guidance $36-40M; retires $15.3M notes
--------------------------------------------------------------------------------

- Q2 2024 revenue $7.8M, down 10% YoY; GAAP gross margin 33% vs 27% in Q2 2023.
- GAAP operating expense $19.6M, down 53% YoY; non-GAAP $18.8M, down 46%.
- Cash and securities $30.3M as of June 30, with $11.4M restricted; $20M in debentures outstanding.
- Retired $15.3M convertible notes for $17.6M redemption plus $2.2M fee, funded by $18M private placement of senior secured convertible debentures.
- Guides full year 2024 revenue $36-40M; Q3 2024 revenue expected $7.9-8.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000141169024000046/0001411690-24-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000141169024000046/bngo-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001411690-24-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer